Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Andrx Fortamet Clears FDA; Dosing Convenience Over Glucophage XR Will Be Focus

This article was originally published in The Pink Sheet Daily

Executive Summary

Patients will be able to achieve optimal daily metformin dose with half as many tablets as Glucophage XR and generics. Andrx is also touting the smaller size of the pills. Fortamet will launch in May.

You may also be interested in...



Andrx Fortamet Picks Up Exclusivity

Andrx' Fortamet (metformin extended-release) has received three years of Waxman/Hatch marketing exclusivity, the company said June 7

Andrx Fortamet Picks Up Exclusivity

Andrx' Fortamet (metformin extended-release) has received three years of Waxman/Hatch marketing exclusivity, the company said June 7

Andrx Fortamet Paragraph IV Certifications

FDA approval of Andrx' Fortamet (metformin extended-release) could be delayed by the company's newly filed Paragraph IV certifications against Bristol-Myers Squibb'sGlucophage XR patents

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS059253

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel